RENEURON GROUP PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.375 GBX | -2.17% |
|
-.--% | -3.57% |
| Apr. 17 | ReNeuron Group Reports CFO Resignation | MT |
| Apr. 17 | ReNeuron CFO steps down to pursue other opportunities | AN |
Presenter SpeechMichael Hunt (Executives)Okay. Well, good morning, everyone, and welcome to Re...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
Calendar
2024-07-10
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.57% | 2.41M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +46.68% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- RENE Stock
- News ReNeuron Group plc
- Transcript : ReNeuron Group plc, 2012 Earnings Call, Jun 28, 2012